Molecular structure of YC-1, CAS Number: 170632-47-0
YC-1 (CAS 170632-47-0)
See product citations (9)
Alternate Names:
5-[1-(phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol
Application:
YC-1 is an agent that can activate sGC independent of nitric oxide activation
CAS Number:
170632-47-0
Purity:
>99%
Molecular Weight:
304.34
Molecular Formula:
C19H16N2O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
YC-1 can activate platelet soluble GCS (guanylate cylcase) indepedent of nitric oxide activation. It has the ability to inhibit aggregation of platelets and increase the platelets cAMP and cGMP content, as well as act as an antithrombotic compound. Data shows that the highest activation of GCS is observed in the presence of YC-1. The compound can suppress HIF-1 alpha activity in neonatal rat ventricular myocytes. Research shows that GCS activators (YC-1) might have the ability to activate the sGC/cGMP/PKG pathway and influence the activation of Ras/Raf-1/p44/42 MAPK. YC-1 is an activator of GCS (guanylate cylcase). YC-1 is an inhibitor of HIF-1 alpha.
YC-1 (CAS 170632-47-0) References
- Versatile pharmacological actions of YC-1: anti-platelet to anticancer. | Chun, YS., et al. 2004. Cancer Lett. 207: 1-7. PMID: 15127725
- Involvement of Ras/Raf-1/p44/42 MAPK in YC-1-induced cyclooxygenase-2 expression in human pulmonary epithelial cells. | Chang, MS., et al. 2009. Pharmacol Res. 60: 247-53. PMID: 19717011
- The effect of hypoxia-inducible factor 1-alpha on hypoxia-induced apoptosis in primary neonatal rat ventricular myocytes. | Zhou, YF., et al. 2010. Cardiovasc J Afr. 21: 37-41. PMID: 20224844
- Binding of YC-1/BAY 41-2272 to soluble guanylate cyclase: A new perspective to the mechanism of activation. | Pal, B. and Kitagawa, T. 2010. Biochem Biophys Res Commun. 397: 375-9. PMID: 20513359
- YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. | Hung, CC. and Liou, HH. 2011. Invest New Drugs. 29: 1337-46. PMID: 20676745
- YC-1 induces lipid droplet formation in RAW 264.7 macrophages. | Tsui, L., et al. 2016. J Biomed Sci. 23: 2. PMID: 26767504
- YC-1 Inhibits VEGF and Inflammatory Mediators Expression on Experimental Central Retinal Vein Occlusion in Rhesus Monkey. | Yan, Z., et al. 2018. Curr Eye Res. 43: 526-533. PMID: 29364731
- YC-1 Antagonizes Wnt/β-Catenin Signaling Through the EBP1 p42 Isoform in Hepatocellular Carcinoma. | Wu, JY., et al. 2019. Cancers (Basel). 11: PMID: 31086087
- YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells. | Hu, H., et al. 2020. Eur J Pharmacol. 874: 172961. PMID: 32044322
- YC-1 sensitizes the antitumor effects of boron neutron capture therapy in hypoxic tumor cells. | Harada, T., et al. 2020. J Radiat Res. 61: 524-534. PMID: 32367141
- HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib. | Jin, Q., et al. 2021. Oxid Med Cell Longev. 2021: 6633867. PMID: 33763171
- Advances in antitumor research of HIF-1α inhibitor YC-1 and its derivatives. | Ouyang, C., et al. 2023. Bioorg Chem. 133: 106400. PMID: 36739684
- YC-1, a novel activator of platelet guanylate cyclase. | Ko, FN., et al. 1994. Blood. 84: 4226-33. PMID: 7527671
- YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. | Wu, CC., et al. 1995. Br J Pharmacol. 116: 1973-8. PMID: 8640334
- Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. | Stone, JR. and Marletta, MA. 1998. Chem Biol. 5: 255-61. PMID: 9646941
Inhibitor of:
Ang-4, Arnt 2, COL6A2, DHRS6, EG623186, H1T2, HHV-4 EBNA-2, HID, HIF-1 alpha, HIF-3α, JMJD2C, Lamin B receptor, LOXL4, Mettl7a2-Higd1c, PASD1, sGC α2I, sGC β1, sGC β2, Sox-14, SPT4, Stra13, Sval1, VHL, and ZBRK1.Activator of:
α-protein kinase 3, 1110002N22Rik, 1190003K10Rik, 1200011I18Rik, 2310007F21Rik, acrogranin, ADAM15, Ang-1, ATPBD4, BC031181, CA IX, cGKI α, CHCHD5, CMV gB, CNG-β3, CNG-1β, CNG-2, CNG-4, CTRP5, Dlx-6, EF-CBP2, GCAP1, GCS, GCS-α-2, GCS-β-1, GI24, GNL3L, HHV-8 K14, HIGD1C, HMW-Guanylin, HOP-1, Integrin α8, KPL2, LZTFL1, METT5D1, MPP7, mPRδ, MRGG, MRP-L32, neuropilin, NOC4L, NPR-A, NPR-B, NPY2-R, NTN, Ost1, PCBP4, PCYOX1L, PDGF-C, Relaxin Receptor 4, Rev-erb alpha, ROS-GC1, ROS-GC2, sGC α1, sGC α2, sGC α2I, sGC β2, SPATA24, Testican-1, Tie-2, WBSCR17, XTRP2, and ZEB1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
YC-1, 1 mg | sc-202856 | 1 mg | $33.00 | |||
YC-1, 5 mg | sc-202856A | 5 mg | $124.00 | |||
YC-1, 10 mg | sc-202856B | 10 mg | $218.00 | |||
YC-1, 50 mg | sc-202856C | 50 mg | $947.00 |